by Market Overview
Antibiotics are medications that fight against bacterial infections by either killing or inhibiting the growth of bacteria. However, some bacteria have developed resistance mechanisms to various antibiotics, making the infections caused by them difficult to treat. This is known as antibiotic resistance. The global antibiotic resistance market consists of various drugs and therapeutic agents that help to combat antibiotic-resistant bacteria. Some of the common antibiotic-resistant bacteria are Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae, drug-resistant Salmonella, drug-resistant Escherichia coli, drug-resistant Neisseria gonorrhoeae, etc. Antibiotic resistance is becoming a serious global health issue and is considered as one of the biggest public health challenges of the 21st century.
The Global antibiotic resistance market is estimated to be valued at US$ 8.83 BN in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.
Key Takeaways
Key Players: Key players operating in the Global Antibiotic Resistance Market Size are Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, and NEMESIS BIOSCIENCE LTD.
Key Opportunities: Increasing incidence of hospital-acquired infections and new product launches are expected to create lucrative opportunities for players in the antibiotic resistance market.
Global Expansion: Rising initiatives by governments and private organizations for R&D of novel drug candidates and rapid penetration of these drugs in developing countries are fueling the global antibiotic resistance market growth.
Market Drivers
One of the major drivers of the antibiotic resistance market is the increasing incidence of hospital-acquired infections (HAIs). HAIs are difficult to treat due to antibiotic-resistant pathogens. According to the Centers for Disease Control and Prevention, more than 2.8 million HAIs occur annually in the U.S., out of which nearly 99,000 patients die as a direct result of these infections. Moreover, the overuse and misuse of antibiotics are driving the emergence of antibiotic resistance. Growing bacterial resistance reduces the effectiveness of available antibiotics used to treat various infections. This is further boosting the demand for novel anti-bacterial treatments for antibiotic-resistant bacterial strains.
PEST Analysis
Political: The antibiotic resistance market is influenced by various regulations and policies issued by governments and regulatory authorities across nations to curb the growth of antibiotic-resistant infections.
Economic: Rising healthcare expenditure worldwide as well as growing generic drug markets are providing opportunities for market players to develop affordable alternatives, thereby driving the antibiotic resistance market growth.
Social: Increasing awareness about antibiotic resistance and need for novel drugs globally is promoting research and development activities in this market.
Technological: Advancements in biotechnology and research in new drug development are helping companies to introduce novel treatment options against antibiotic-resistant infections. Combination therapies and targeted drug delivery systems are also being explored.
North America is currently the largest regional market for antibiotic resistance in terms of value, supported by the growing prevalence of antibiotic-resistant infections, rising healthcare spending, presence of key market players, and streamlined regulatory approval process.
Asia Pacific is poised to be the fastest growing regional market over the forecast period due to fast expanding generic drug markets in India and China, increasing expenditure on healthcare infrastructure, and growing government focus on tackling antimicrobial resistance
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
